| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/29/2011 | WO2011050068A3 Bivalent diazo bicyclic smac mimetics and the uses thereof |
| 09/29/2011 | WO2011049405A3 Optical imaging contrast agent, use and device thereof |
| 09/29/2011 | WO2011047135A3 Compositions and methods for treating bladder cancer |
| 09/29/2011 | WO2011046381A3 COMPOSITION FOR INHIBITING TGF-β COMPRISING IMIDAZOPURINE DERIVATIVES |
| 09/29/2011 | WO2011041512A3 Compositions and methods for treating mlv-infection, and preventing and treating mlv-initiated diseases |
| 09/29/2011 | US20110239316 ANTI-cMET ANTIBODY |
| 09/29/2011 | US20110238003 Method for systemic drug delivery through the nail |
| 09/29/2011 | US20110238000 Polymer-conjugated albumin hydrogels for controlled release of therapeutic agents |
| 09/29/2011 | US20110237783 Hydrazonopyrazole derivatives and their use as therapeutics |
| 09/29/2011 | US20110237686 Formulations and methods of use |
| 09/29/2011 | US20110237676 Spermicidal and microbicidal compositions |
| 09/29/2011 | US20110237659 Chromenone derivatives as trpv3 antagonists |
| 09/29/2011 | US20110237654 Method to inhibit cell growth using oligonucleotides |
| 09/29/2011 | US20110237652 Detection and destruction of cancer cells using programmed genetic vectors |
| 09/29/2011 | US20110237651 Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo |
| 09/29/2011 | US20110237650 Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
| 09/29/2011 | US20110237649 Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
| 09/29/2011 | US20110237647 Inhibitory rna for modulating the molecular function of zfat gene |
| 09/29/2011 | US20110237645 USE OF RNAi TECHNOLOGY TO INHIBIT ASIC3 |
| 09/29/2011 | US20110237644 Ubiquitin specific proteases responsible for mcl-1 stability and uses thereof |
| 09/29/2011 | US20110237641 Substituted pyrazoles, compositions containing these, method of production and use |
| 09/29/2011 | US20110237631 Selective Glycosidase Inhibitors and Uses Thereof |
| 09/29/2011 | US20110237625 SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-á MODULATORS |
| 09/29/2011 | US20110237624 Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents |
| 09/29/2011 | US20110237620 Heterocyclic compound and use thereof |
| 09/29/2011 | US20110237617 Thieno[2,3-c] isoquinolines for use as inhibitors of parp |
| 09/29/2011 | US20110237610 Quinazoline Derivatives as Antiproliferative Agents |
| 09/29/2011 | US20110237609 Antifolate compositions |
| 09/29/2011 | US20110237608 Pyridopyrimidinone Inhibitors of PI3Kalpha |
| 09/29/2011 | US20110237606 3-Deazaneplanocin Derivatives |
| 09/29/2011 | US20110237605 Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative |
| 09/29/2011 | US20110237601 Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
| 09/29/2011 | US20110237599 Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| 09/29/2011 | US20110237598 New compounds |
| 09/29/2011 | US20110237596 Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| 09/29/2011 | US20110237592 Substituted amido phenoxybenzamides |
| 09/29/2011 | US20110237589 Guanidine compounds, and use thereof as binding partners for 5-ht5 receptors |
| 09/29/2011 | US20110237587 1,3,5-Triazine-2,4,6-Triamine Compound or Pharmaceutical Acceptable Salt Thereof, and Pharmaceutical Composition Comprising the Same |
| 09/29/2011 | US20110237586 Biaryl compositions and methods for modulating a kinase cascade |
| 09/29/2011 | US20110237585 Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase |
| 09/29/2011 | US20110237584 Kynurenine production inhibitor |
| 09/29/2011 | US20110237583 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer |
| 09/29/2011 | US20110237581 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| 09/29/2011 | US20110237574 Use of modified pyrimidine compounds to promote stem cell migration and proliferation |
| 09/29/2011 | US20110237573 N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| 09/29/2011 | US20110237572 Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives |
| 09/29/2011 | US20110237566 Therapeutic Macrolide Compounds and Their Use |
| 09/29/2011 | US20110237560 Modulating and/or detecting activation induced deaminase and methods of use thereof |
| 09/29/2011 | US20110237557 Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3 |
| 09/29/2011 | US20110237556 (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-HYDROXYVITAMIN D3 |
| 09/29/2011 | US20110237553 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| 09/29/2011 | US20110237550 5-azaindole bisphosphonates |
| 09/29/2011 | US20110237545 Trihydroxy polyunsaturated eicosanoid derivatives |
| 09/29/2011 | US20110237543 Composition for Prevention or Treatment of Eye Diseases |
| 09/29/2011 | US20110237540 Cyclodextrin-based polymers for therapeutic delivery |
| 09/29/2011 | US20110237538 Treatment of lysosomal storage disorders and other proteostatic diseases |
| 09/29/2011 | US20110237520 Anticancer Compounds |
| 09/29/2011 | US20110237519 Hematopoietic Growth Factor Inducible Neurokinin-1 Gene and Uses Thereof |
| 09/29/2011 | US20110237518 Method for treating or preventing bladder cancer using the depdc1 polypeptide |
| 09/29/2011 | US20110237517 Iap inhibitors |
| 09/29/2011 | US20110237511 EP4 Receptor Agonist, Compositions and Methods Thereof |
| 09/29/2011 | US20110237507 Methods of protecting against apoptosis using lipopeptides |
| 09/29/2011 | US20110237499 Hybrid tripyrrole-octaarginine compounds and their use as medicament in the treatment of cancer and microbial illnesses |
| 09/29/2011 | US20110237498 Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| 09/29/2011 | US20110237497 Compositions of a v-atpase inhibitor in combination with a glucocorticoid receptor ligand and methods of use |
| 09/29/2011 | US20110237496 Antinecrotic activity of alpha 1-antitrypsin |
| 09/29/2011 | US20110237492 Treatment of diseases and conditions mediated by increased phosphorylation |
| 09/29/2011 | US20110236994 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays |
| 09/29/2011 | US20110236511 Herbal formulations |
| 09/29/2011 | US20110236507 Inhibition of dna polymerases to augment chemotherapeutic and antimicrobial agents |
| 09/29/2011 | US20110236506 Pharmaceutical association containing lipoic acid and hydroxycitric acid as active ingredients |
| 09/29/2011 | US20110236501 Injectable dual delivery allograph bone/polymer composite for treatment of open fractures |
| 09/29/2011 | US20110236495 Anti-cancer nanoparticle compositions and methods of use |
| 09/29/2011 | US20110236472 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| 09/29/2011 | US20110236471 Platinum complexes and methods for inhibiting tumor cell proliferation |
| 09/29/2011 | US20110236456 Implantable device for the delivery of histrelin and methods of use thereof |
| 09/29/2011 | US20110236454 Injectable drug delivery formulation |
| 09/29/2011 | US20110236428 Combination therapy with peptide epoxyketones |
| 09/29/2011 | US20110236427 Antagonists of NR2F6 For Augmenting The Immune Response |
| 09/29/2011 | US20110236415 Virulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| 09/29/2011 | US20110236411 MHC Multimers in Tuberculosis Diagnostics, Vaccine and Therapeutics |
| 09/29/2011 | US20110236406 Immunogenic compositions comprising hmgb1 polypeptides |
| 09/29/2011 | US20110236403 Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy |
| 09/29/2011 | US20110236402 Enhancement of light activated therapy by immune augmentation using anti-ctla-4 antibody |
| 09/29/2011 | US20110236401 Compositions and methods for modulating lymphocyte activity |
| 09/29/2011 | US20110236397 Limited proteolysis of cd2ap and progression of renal disease |
| 09/29/2011 | US20110236396 Methods and compositions for diagnosing and treating a colorectal adenocarcinoma |
| 09/29/2011 | US20110236393 Monoclonal antibody production in b cells and uses therof |
| 09/29/2011 | US20110236389 Human Angiostatin Interacting and Tumor Metastasis Involving Protein Variants and Uses Thereof |
| 09/29/2011 | US20110236388 Bispecific, bivalent anti-vegf/anti-ang-2 antibodies |
| 09/29/2011 | US20110236387 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| 09/29/2011 | US20110236385 Blocking mesothelin peptide fragments |
| 09/29/2011 | US20110236380 Ligands that bind il-13 |
| 09/29/2011 | US20110236379 Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitor |
| 09/29/2011 | US20110236377 Hepatocyte Growth Factor (HGF) Binding Proteins |
| 09/29/2011 | US20110236374 Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2 |
| 09/29/2011 | US20110236367 Rat cathespin dipeptidyl peptidase i (dppi): crystal structure and its uses |
| 09/29/2011 | US20110236366 Production and uses of type i ribosome inactivating proteins |
| 09/29/2011 | US20110236365 Method for protecting and treating at least one muscarinic receptor from dysfunction resulting from free radical damage |
| 09/29/2011 | US20110236363 System and method for producing t cells |